SHAREHOLDER ALERT: Investigation of FibroGen, Inc. Announced by Holzer & Holzer, LLC

Atlanta, Georgia--(Newsfile Corp. - April 7, 2021) - Holzer & Holzer, LLC is investigating whether FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) complied with federal securities laws. On April 6, 2021, FibroGen made an announcement to provide "clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease." The price of FibroGen shares fell following the announcement.

If you purchased shares of FibroGen and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at or by toll-free telephone at (888) 508-6832 to discuss your legal rights or visit the firm's website at

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.

Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)

To view the source version of this press release, please visit